ArticleJournal of virology2001
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Blockade ofmBio · 2025Article
- Evaluation of Antimicrobial Activity ofPlants (Basel, Switzerland) · 2023Article
- High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs.Nature communications · 2021Article
- Advances in understanding the initiation of HIV-1 reverse transcription.Current opinion in structural biology · 2020Review
- Reconstitution and visualization of HIV-1 capsid-dependent replication and integration in vitro.Science (New York, N.Y.) · 2020Article
- Sensing of HIV-1 Entry Triggers a Type I Interferon Response in Human Primary Macrophages.Journal of virology · 2017Article
- A cell-based strategy to assess intrinsic inhibition efficiencies of HIV-1 reverse transcriptase inhibitors.Antimicrobial agents and chemotherapy · 2015Article
- Comparative study of rosmarinic acid content in some plants of Labiatae family.Pharmacognosy magazine · 2012Article
- Initiation complex dynamics direct the transitions between distinct phases of early HIV reverse transcription.Nature structural & molecular biology · 2010Article
- Novel paradigms for drug discovery: computational multitarget screening.Trends in pharmacological sciences · 2008Review
- Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.Antimicrobial agents and chemotherapy · 2007Article
- Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication.Journal of virology · 2003Article
- Gag-Pol supplied in trans is efficiently packaged and supports viral function in human immunodeficiency virus type 1.Journal of virology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early HIV-1 reverse transcription can be separated into initiation and elongation phases. Here we show, using PCR analysis of negative-strand strong-stop DNA [(-)ssDNA] synthesis in intact virus, that different reverse transcriptase (RT) inhibitors affect distinct phases of early natural endogenous reverse transcription (NERT). The effects of nevirapine on NERT were consistent with a mechanism of action including both specific and nonspecific binding events. The nonspecific component of this inhibition targeted the elongation reaction, whereas the specific effect seemed principally to be directed at very early events (initiation or the initiation-elongation switch). In contrast, foscarnet and the nucleoside analog ddATP inhibited both early and late (-)ssDNA synthesis in a similar manner. We also examined compounds that targeted other viral proteins and found that Ro24-7429 (a Tat antagonist) and rosmarinic acid (an integrase inhibitor) also directly inhibited RT. Our results indicate that NERT can be used to identify and evaluate compounds that directly target the reverse transcription complex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.